Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   MDxHealth   /   MDxHealth nieuws 2014

MDxHealth nieuws 2014

Volgen
5.395 Posts
Pagina: «« 1 ... 58 59 60 61 62 ... 270 »» | Laatste | Omlaag ↓
  8. Pelikapuntzak 24 maart 2014 18:09
    Exact Sciences nog behoorlijk in het groen met een sterk bovengemiddeld dagvolume. MDx mocht helaas niet hoger, van mij had het gemogen. Waar velen bang voor waren nl. een koersval is achterwege gebleven. Geen garantie voor morgen maar de week had slechter kunnen beginnen. Zie rest beurs.
  10. Boeren 24 maart 2014 18:35
    Wat kan er donderdag nog mis gaan?.. Ben benieuwd naar het effect op de koers van MDxHealth

    Bron: seekingalpha.com/article/2104963-exac...

    Exact Sciences' Stool-DNA-Based Colorectal Cancer Screening Test Likely To Get Favorable Review On Its PMA
    Mar. 24, 2014 9:11 AM ET

    Exact Sciences (EXAS) is a molecular diagnostics company focused on colorectal cancer.
    On March 27, 2014, the Molecular and Clinical Genetics Panel will review the premarket approval application (PMA) for the company's Cologuard stool-DNA-based, non-invasive colorectal cancer screening test.
    After carefully reviewing the published scientific evidence, we believe that Cologuard will receive favorable review on its PMA.
    Exact Sciences (EXAS) is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. On March 27, 2014, the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee of the U.S. Food and Drug Administration will review the premarket approval application (PMA) for the company's Cologuard stool-DNA-based, non-invasive colorectal cancer screening test. After carefully reviewing the published scientific evidence, we believe that Cologuard will receive favorable review on its PMA.

    Over 600,000 people die from colorectal cancer (CRC) annually worldwide [1]. It is the second leading cause of cancer deaths in the US [2]. According to the Journal of the National Cancer Institute, CRC is often considered the most preventable, yet least prevented cancer. Nearly 50 percent of those age 50 and older have not been screened as recommended. Over 75% of CRC occurs in people with no genetic risks. Most common risk factors include increasing age and unhealthy lifestyle choices [3]. People with inflammatory bowel disease or family history of genetic syndromes such as familial adenomatous polyposis are at higher risk of CRC [3]. Most deaths due to CRC are associated with metastatic disease. CRC confined in the colon is curable by physical removal of the cancer. Standard screening methods are invasive colonoscopy and sigmoidoscopy, which involve a lighted flexible tube passed through the anus, providing a visual diagnosis and opportunity for biopsy. Fecal occult blood test (FOBT) is a non-invasive test, which checks for hidden blood in fecal material by detecting hemoglobin protein stool samples [4].

    Cologuard assays exfoliated DNA markers (methylated BMP3 and NDRG4, mutant KRAS, beta-actin) and fecal hemoglobin to detect CRC and its precursors, advanced adenoma (AA) and sessile serrated adenoma (SSA) [5]. In the company's early trial, using 385 cases (133 AA + 252 CRC) and 293 controls collected from 5 sites, their stool DNA ((sDNA)) assay showed 85% detection sensitivity for CRC and 63% detection sensitivity for AA>1cm at 90% specificity cut-off, compared to the reference colonoscopy method [6]. Importantly, sDNA detection rate was not affected by neoplasm site, indicating that sDNA assay can detect both left-sided and right-sided colorectal neoplasms, in contrast to all conventional screening methods, which are biased toward detecting left-sided colorectal neoplasms. Later, the company conducted another study on independent set of 207 cases (30 SSA + 80 AA + 93 CRC) and 796 controls to test their automated sDNA assay. In the study, they achieved 98% (n=98) detection rate for CRC at 90% specificity cut-off [5]. For AA/SSA, the detection sensitivity increases with increasing lesion size, from 60% (n=84) for AA/SSA>1cm to 83% (n=24) for AA/SSA>3cm. In the preliminary results from the company's largest trial, so-called 'DeeP-C' study where >12,000 patients were enrolled from 90 sites, the company claims to achieve 92% sensitivity for CRC and 66% for AA>2cm and 42% for all pre-cancerous polyps [7].

    FOBT, a comparable non-invasive screening method currently available, appears much less sensitive than sDNA assay in detecting CRC and its precursors. Other researchers have reported FOBT detection rate as 13% for CRC, 11% for AA, and 5% for minor polyps [8]. EXAS also conducted a study to compare the performance between Cologuard and FOBT in detecting SSA using 29 SSA=1cm and 232 controls with no polyps and concluded that a single marker in Cologuard (mBMP3) achieved 66% detection sensitivity at 91% specificity cut-off while FOBT achieved 10% [9]. They also found that Hemoglobin marker alone showed no discrimination between cases and controls, corroborating the low detection rate by FOBT. The company also claims that they exceeded all end-points including comparison with FOBT in their large-scale DeeP-C trial, although the data are not public yet [7].

    Compared to existing methods, Cologuard offers a reliable CRC screening choice in a completely non-invasive form. If the company successfully obtains coverage from the Centers for Medicare and Medicaid Services for Cologuard, it could at least completely replace FOBT and/or increase the CRC screening market size by involving people who would otherwise not be screened for CRC due to the invasive colonoscopy procedure. In short, we believe Cologuard will be approved by the FDA sometimes this year and EXAS stock is a strong buy.

  12. grand sasso 24 maart 2014 21:05
    Exact Sciences' Stool-DNA-Based Colorectal Cancer Screening Test Likely To Get Favorable Review On Its PMA by Beacon VP Investments
    This article was published on Mon, Mar. 24, 9:11 AM ET

    Read the full article now »

    Zie Seeking alpha.Goed onderbouwd verhaal.

    ------------------------------------------------------------------------------

  13. mickjagger2 24 maart 2014 21:14
    quote:

    grand sasso schreef op 24 maart 2014 21:05:

    Exact Sciences' Stool-DNA-Based Colorectal Cancer Screening Test Likely To Get Favorable Review On Its PMA by Beacon VP Investments
    This article was published on Mon, Mar. 24, 9:11 AM ET

    Read the full article now »

    Zie Seeking alpha.Goed onderbouwd verhaal.

    ------------------------------------------------------------------------------


    ?????
  15. [verwijderd] 24 maart 2014 21:30
    Mag best eens gezegd worden vind ik: dank aan ieder op dit forum voor de opbouwende en bemoedigende berichtgevingen die ook met persberichten en feiten onderbouwd worden, waardoor eventuele wishfull-thinking, dat je zoveel op andere forums leest, aan waarde inboet doordat zij gerechtvaardigd wordt door eerdergenoemde berichtgevingen.
    Wellicht had ik anders toch in een moment van zwakte (noem ik het), mijn winst verzilverd (=niet verkeerd), terwijl er nog zoveel meer in het vat zit in de (nabije) toekomst.
    Alleen nu de koers nog verder omhoog. Geduld en bijkopen zou ik doen als je nog geld hebt.
    SUCCES IEDER !!!!!!
  16. grand sasso 24 maart 2014 22:09

    @MICK jACKER. Sorry, laat thuis gekomen , en in mijn enthousiasme gelijk hier gepost, zonder eerst terug te lezen.
    Mijn te snelle reactie werd met name ook gestuurd door een verbeterd goed gevoel t.o.v Exact sciences, immers vorige week stapte een bestuurder op,
    en werd het embargo voor publicatie in "the New England Yournal of Medicine
    ( te vroeg ) gelicht.
    De sterke koers wisselingen weerspiegelden het een en ander.
    We houden Exact de komende dagen scherp in het oog.

    Veel succes allen de komende tijd.

    Gr.Frans
  18. [verwijderd] 25 maart 2014 08:46
    Goedemorgen allemaal

    Exact Sciences

    14.22 +0.66 (4.87%)
    After Hours: 14.25 +0.03 (0.21%)
    Mar 24, 6:02PM EDT
    NASDAQ real-time data - Disclaimer
    Currency in USD
    Range 13.61 - 14.43
    52 week 6.93 - 15.60
    Open 14.20
    Vol / Avg. 3.54M/1.39M
    Mkt cap 1.01B
    P/E -
    Div/yield -
    EPS -0.69
    Shares 70.92M
    Beta 1.55
    Inst. own 91%

    Opvallende info Exact Science
    Alles gisteren negatief , Exact S. sluit 4,87% hoger met 3 keer zo hoog volume als gemiddeld .
    Kijk eens onderaan het overzichtje :

    Inst. own 91%.
    Dit is natuurlijk zeer hoog . Een hele lage freefloat en heel veel vertrouwen van de grote jongens(en meiden)

    Ik verwacht dat MDXhealth ook binnen 1-2 jaar naar hoge % inst.own zal groeien .

    Nu is het laatst bekende cijfer van half 2013 / 51% .

    Zodra we boven de 5 euro uitkomen kan het wel eens hard gaan met dit % .
5.395 Posts
Pagina: «« 1 ... 58 59 60 61 62 ... 270 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum